Lineage Cell TherapeuticsLCTX +4.92%78 Quick Ratio is 6.89 as of Mar. 2026, which is 74% above its 10-year median of 3.97. GuruFocus rates LCTX with a GF Score™ of 78/100 and a GF Value™ of $1.33 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Lineage Cell Therapeutics ranks better than 69.07% on this metric.
Lineage Cell Therapeutics has a quick ratio of 6.89. It generally indicates good short-term financial strength.
The historical rank and industry rank for Lineage Cell Therapeutics's Quick Ratio or its related term are showing as below:
LCTX'
s Quick Ratio Range Over the Past 10 Years
Min: 1.89 Med: 3.97 Max: 10.58
Current: 6.89
During the past 13 years, Lineage Cell Therapeutics's highest Quick Ratio was 10.58. The lowest was 1.89. And the median was 3.97.
LCTX's Quick Ratio is ranked better than 69.07% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs LCTX: 6.89
Lineage Cell Therapeutics (AMEX:LCTX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Lineage Cell Therapeutics Quick Ratio Related Terms
Lineage Cell Therapeutics Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lineage Cell Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Lineage Cell Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics (LCTX) has a Quick Ratio of 6.89 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lineage Cell Therapeutics and its competitors. This is 74% above median its historical median of 3.97. Over the past decade, Lineage Cell Therapeutics' Quick Ratio has ranged from 1.89 to 10.58. According to the industry distribution chart, Lineage Cell Therapeutics ranks #438 out of 1416 companies in the Biotechnology industry, placing it in the top 30.9%.
Is Lineage Cell Therapeutics' Quick Ratio too high?
Lineage Cell Therapeutics' current Quick Ratio of 6.89 is 74% above median its 10-year median of 3.97. Over the past 10 years, this metric has ranged from a low of 1.89 to a high of 10.58. The Biotechnology industry median Quick Ratio is 3.60. Lineage Cell Therapeutics' value of 6.89 is 91.4% above this industry median. Based on the distribution chart, Lineage Cell Therapeutics ranks #438 out of 1416 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Quick Ratio compare to FATE and ABEO?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #438 out of 1416 companies for Quick Ratio. This puts Lineage Cell Therapeutics in the upper half of its industry. The industry median Quick Ratio is 3.60. Lineage Cell Therapeutics' value of 6.89 is 91.4% above this benchmark. Historically, Lineage Cell Therapeutics' own Quick Ratio has ranged from 1.89 to 10.58 over the past decade. While the company's 10-year median is 3.97 vs. the industry median of 3.60, Lineage Cell Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lineage Cell Therapeutics's current Quick Ratio of 6.89 is 91.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Lineage Cell Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current Quick Ratio is 6.89, which is 74% above median its own 10-year median of 3.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.28 — trading 3.8% below its estimated fair value. The current Quick Ratio is 6.89, which is 74% above median its 10-year median of 3.97 and 91.4% above the Biotechnology industry median of 3.60. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Quick Ratio is 6.89 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of $1.28 is trading 3.8% below its estimated GF Value™ of $1.33.
GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.
Key valuation signals for LCTX:
Quick Ratio: 6.89 (74% above median its 10-year median of 3.97)
GF Value™: $1.33 vs. price of $1.28 (3.8% below fair value)
Industry Position: 91.4% above the Biotechnology median (#438 of 1416)
No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score
Get the complete analysis for LCTX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCTX has been successfully added to your 
